Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHK-Cu (Scalp) vs Melanotan I (Afamelanotide)
An educational, source-based comparison of GHK-Cu (Scalp) and Melanotan I (Afamelanotide) — how each peptide works, what it's researched for, and what to know before going deeper.
Topical GHK-Cu applied to the scalp has been studied for its ability to enlarge hair follicles, prolong the anagen growth phase, and improve perifollicular vascularization through copper-dependent gene modulation.
- Follicle size and anagen phase
- Perifollicular angiogenesis
- Post-procedure scalp recovery (microneedling, transplant)
- • Topical use has a long cosmetic safety record.
- • Not a replacement for evidence-based therapies like minoxidil or finasteride.
Selective MC1R agonist FDA-approved for erythropoietic protoporphyria.
A selective melanocortin-1 receptor (MC1R) agonist that stimulates eumelanin production in melanocytes. FDA-approved (Scenesse) as an implant for erythropoietic protoporphyria, a rare light-sensitive disorder.
- Erythropoietic protoporphyria (FDA-approved)
- UV-independent tanning (research)
- Photoprotection in photosensitivity disorders
- • FDA-approved for EPP via implant formulation only.
- • Not approved for cosmetic tanning.
- • Monitoring for new/changing moles recommended.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHK-Cu (Scalp) | Copper peptides and hair growth | Journal of the American Academy of Dermatology | 2007 | Reported follicular stimulation and improved hair density in early trials. |
| Melanotan I (Afamelanotide) | Afamelanotide for erythropoietic protoporphyria | New England Journal of Medicine | 2015 | Phase 3 trials showed significant pain reduction and sun tolerance. |
Side-effect & safety grid
- Topical use has a long cosmetic safety record.
- Not a replacement for evidence-based therapies like minoxidil or finasteride.
- FDA-approved for EPP via implant formulation only.
- Not approved for cosmetic tanning.
- Monitoring for new/changing moles recommended.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHK-Cu (Scalp) vs Melanotan I (Afamelanotide) — Key differences
- Class: GHK-Cu (Scalp) is classified as Hair · Follicle Health, while Melanotan I (Afamelanotide) is Pigmentation · Melanocortin.
- Primary research focus: GHK-Cu (Scalp) — follicle size and anagen phase; Melanotan I (Afamelanotide) — erythropoietic protoporphyria (fda-approved).
- Tag: Hair vs Skin · Pigmentation.